Business
510(K) approval for LiquiBand
510(K) approval for LiquiBand.
About this update from Advanced Medical Solutions Group Plc
[{"type":"text","content":"\n RNS Number : 2134K Advanced Medical Solutions Grp PLC 15 April 2010 \n \n\nFor immediate release: 15 April 2010 \n \nAdvanced Medical Solutions Group plc\n(\"AMS\" or the \"Group\")\n \n510(k) clearance for LiquiBand® tissue adhesive\naimed at closure of surgical wounds in the Operating Room\n \nWinsford, UK: Advanced Medical Solutions Group plc (AIM: AMS.L), the global medical technology company, today announces that it has received 510(k) clearance from the US Food and Drug Administration (FDA) for a topical skin adhesive which is aimed at the closure and protection of surgical incisions in the Operating Room as an alternative to sutures and staples.\n \nContaining a strong, fast setting, cyanoacrylate adhesive, the product has a dual applicator which allows initial closure of the surgical incision followed by the application of an adhesive film to help protect the wound site from infection or breakdown.\n \nAs part of the LiquiBand® Topical Skin Adhesive range, this product is aimed at the closure and protection of surgical wounds and is particularly suited for laparoscopic procedures.\n \nTogether with the two products launched into the US in December 2009, this approval now provides AMS with a broad range of topical tissue adhesives for closure of trauma wounds and surgical incisions for the US Acute Care and Alternate Site market segments.\n \nCommenting on this announcement, Dr. Don Evans, Chief Executive Officer of Advanced Medical Solutions commented:\n \n\"This latest 510(K) will increase our coverage of the US tissue adhesives market from what we believe to be around 70% to some 90%. It will also increase our penetration into the important US Operating Room segment.\n \n\"Our LiquiBand® range is already well proven and successful in Europe. Together with the strong marketing and distribution partners we are putting in place, this latest FDA approval further increases our ability to penetrate the US market, which is currently estimated at US$200 million and growing at around 15%.\n \n\"The first few months of our US marketing activity has been very encouraging and we are confident that this new dual applicator product will underpin the momentum we are already seeing.\"\n \n-ends -\n \nFor further information, please visit www.admedsol...